Data from preclinical models of Parkinson’s disease indicate that nicotine and selective α7 nAChR agonists reduce microglia activation and neuroinflammation, and prevent nigro-striatal dopamine-neuronal loss [206, 207]. The gene discussed is CHRNA7; the disease is Parkinson disease.